Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals (BCRX) announced the grant of inducement stock options to 12 new employees totaling 213,000 shares. The options, exercisable at $3.44 per share, were awarded on September 30, 2020, in line with Nasdaq Listing Rule 5635(c)(4). They will vest in four annual installments, subject to continued employment, and have a 10-year term. This initiative highlights BioCryst's commitment to attracting talent necessary for advancing its drug development programs, including treatments for rare diseases and COVID-19.

BioCryst Pharmaceuticals (BCRX) announced the grant of inducement stock options to 22 new employees. A total of 333,000 shares were allocated at an exercise price of $4.15, equal to the stock's closing price prior to the grant date. The options will vest over four years, starting one year after the grant, and have a 10-year term. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent critical for BioCryst's growth, particularly as it advances its novel treatments for rare diseases.

BioCryst Pharmaceuticals (BCRX) announced the U.S. Department of Health and Human Services (HHS) will purchase 10,000 additional doses of RAPIVAB (peramivir injection) for approximately $7 million. This order supports the Strategic National Stockpile amid concerns over the influenza season during the COVID-19 pandemic. The purchase is part of a broader $34.7 million contract from 2018, allowing procurement of up to 50,000 doses over five years. RAPIVAB is approved for treating acute uncomplicated influenza in patients aged 2 and older.

BioCryst Pharmaceuticals (BCRX) announced a $44 million contract from NIAID and an additional $3 million to further develop galidesivir, a broad-spectrum antiviral. The funds will support ongoing clinical trials, including a phase 2 trial for non-hospitalized COVID-19 patients and a trial assessing dosing for patients with renal impairment. Galidesivir has shown effectiveness against various RNA viruses, and the company is accelerating its manufacturing to increase supply. The contract reflects continued government investment in combating COVID-19 and future viral threats.

BioCryst Pharmaceuticals (BCRX) has received Orphan Drug designation from the FDA for its oral Factor D inhibitor, BCX9930, aimed at treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and severe blood disorder. This designation qualifies BCX9930 for development incentives like tax credits and market exclusivity. Additionally, BCX9930 has also been granted Fast Track designation. Dr. William Sheridan highlighted the unmet medical need BCX9930 addresses, signaling a commitment to advancing this treatment efficiently.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the grant of inducement stock options for 20 new employees, totaling 290,000 shares, effective July 31, 2020. The options, priced at $4.07 per share, reflect the closing stock price the prior day. Vested over four years, they are part of BioCryst's Inducement Equity Incentive Plan and are valid for a decade. The company focuses on developing novel oral treatments for rare diseases, with products like ORLADEYO™ and RAPIVAB® already in various stages of market approval.

BioCryst Pharmaceuticals (BCRX) is set to release its second quarter 2020 financial results on August 6, 2020. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. Interested parties can access the call by dialing specific numbers for domestic and international callers and using the designated conference ID. BioCryst focuses on developing oral small-molecule medicines for rare diseases, with ongoing programs for treatments addressing hereditary angioedema, COVID-19, and other serious conditions.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced findings published in Science Translational Medicine showing that galidesivir demonstrated safety and effective post-exposure prevention against Zika virus in Rhesus macaques. Administered up to 72 hours post-infection, galidesivir reduced viral loads to undetectable levels. The data suggest its potential application against SARS-CoV-2, given the ongoing pandemic. Galidesivir has shown broad-spectrum antiviral activity against over 20 RNA viruses and is currently in a Phase 1 trial for COVID-19 in Brazil.

BioCryst Pharmaceuticals (BCRX) announced the launch of an expanded access program (EAP) for berotralstat, a once-daily oral treatment for hereditary angioedema (HAE). This EAP allows U.S. physicians to request berotralstat for patients unable to access it through clinical trials. The FDA is reviewing a new drug application for berotralstat, with a decision expected by December 3, 2020. BioCryst focuses on developing innovative, oral treatments for rare diseases, with several ongoing drug development programs, including options for COVID-19.